Rifapentine-isoniazid versus isoniazid-alone therapy for tuberculosis prevention among people living with HIV (PLHIV): a systematic review and meta-analysis of randomized trials
Open Access
- 19 February 2026
- journal article
- review article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Abstract
Tuberculosis (TB), a substantial cause of morbidity and mortality among people living with human immunodeficiency virus (PLHIV), accounted for 161,000 deatKeywords
This publication has 22 references indexed in Scilit:
- Completion rate of tuberculosis preventive therapy and incidence of tuberculosis among people living with the Human Immunodeficiency Virus on antiretroviral therapy in Ekurhuleni East subdistrict, Gauteng provincePan African Medical Journal, 2024
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsBMJ, 2021
- Higher adverse drug reactions but better completion rate of twelve-dose weekly rifapentine plus isoniazid comparing with nine-month daily isoniazid for latent tuberculosis infection among patients under maintenance dialysisEuropean Respiratory Journal, 2020
- TuberculosisThe Lancet, 2019
- One Month of Rifapentine plus Isoniazid to Prevent HIV-Related TuberculosisNew England Journal of Medicine, 2019
- Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysisAmerican Journal of Preventive Medicine, 2018
- Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected personsAIDS, 2016
- New Regimens to Prevent Tuberculosis in Adults with HIV InfectionNew England Journal of Medicine, 2011
- Pharmacokinetics of Darunavir/Ritonavir and Rifabutin Coadministered in HIV-Negative Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2010
- Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male VolunteersArchives of Drug Information, 2009